EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease Presented ByProf. Marc Ferrante, KU Leuven, Belgium TrialEVOLVE ConferenceDDW 2023 TypeNews article 13 June 2023 13:56